Abstract

Polycystic ovary syndrome (PCOS) is associated with symptoms of moderate to severe anxiety and depression. Hyperandrogenism is a key feature together with lower levels of the adipocyte hormone adiponectin. Androgen exposure leads to anxiety-like behavior in female offspring while adiponectin is reported to be anxiolytic. Here we test the hypothesis that elevated adiponectin levels protect against the development of androgen-induced anxiety-like behavior. Pregnant mice overexpressing adiponectin (APNtg) and wildtypes were injected with vehicle or dihydrotestosterone to induce prenatal androgenization (PNA) in the offspring. Metabolic profiling and behavioral tests were performed in 4-month-old female offspring. PNA offspring spent more time in the closed arms of the elevated plus maze, indicating anxiety-like behavior. Intriguingly, neither maternal nor offspring adiponectin overexpression prevented an anxiety-like behavior in PNA-exposed offspring. However, adiponectin overexpression in dams had metabolic imprinting effects, shown as lower fat mass and glucose levels in their offspring. While serum adiponectin levels were elevated in APNtg mice, cerebrospinal fluid levels were similar between genotypes. Adiponectin overexpression improved metabolic functions but did not elicit anxiolytic effects in PNA-exposed offspring. These observations might be attributed to increased circulating but unchanged cerebrospinal fluid adiponectin levels in APNtg mice. Thus, increased adiponectin levels in the brain are likely needed to stimulate anxiolytic effects.

Details

Title
Elevated circulating adiponectin levels do not prevent anxiety-like behavior in a PCOS-like mouse model
Author
Samad, Manisha 1 ; Ek, Joakim 1 ; Börchers, Stina 1 ; Krieger, Jean-Philippe 2   VIAFID ORCID Logo  ; Stener-Victorin, Elisabet 3   VIAFID ORCID Logo  ; Skibicka, Karolina P. 4 ; Asterholm, Ingrid Wernstedt 1   VIAFID ORCID Logo  ; Benrick, Anna 5   VIAFID ORCID Logo 

 University of Gothenburg, Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582) 
 University of Gothenburg, Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); University of Zurich-VetSuisse, Institute of Veterinary Pharmacology and Toxicology, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650) 
 Karolinska Institute, Department of Physiology and Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 University of Gothenburg, Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Pennsylvania State University, Department of Nutritional Sciences, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281); Pennsylvania State University, Huck Institutes of the Life Sciences, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281) 
 University of Gothenburg, Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); University of Skövde, School of Health Sciences, Skövde, Sweden (GRID:grid.412798.1) (ISNI:0000 0001 2254 0954) 
Pages
563
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2910057109
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.